U.S., Sept. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07156929) titled 'Kinetics and Metabolism of Nicotinamide Provided as a Dietary Supplementation' on July 28.
Brief Summary: The diet of patients with reduced tryptophan serum levels that are either hospitalized for acute respiratory infection or treated for chronic inflammatory diseases such as inflammatory bowel diseases (in- or outpatients) is supplemented with controlled-ileocolonic-release nicotinamide (CICR-NAM) at doses of 500 mg or 1000 mg per day for four weeks. In the COVit-2 trial (NCT04751604), nicotinamide supplementation including CICR-NAM has been shown to accelerate physical recovery from mild-to-moderate COVID-19 (for publication, see...